CA
NZ
UK
AU
IND
US
DexCom, Inc. (Nasdaq:DXCM)has reported its financial performance for the first quarter of 2025, with notable revenue growth, expanded product reach, and key regulatory milestones that signal continued momentum for the glucose monitoring technology leader.
BriaCell Therapeutics Corp., a clinical-stage biotechnology company, has presented new data from its ongoing pivotal Phase 3 trial of Bria-IMT™, an investigational immunotherapy for metastatic breast cancer (MBC). The study, titled BRIA-ABC (NCT06072612), explores how specific biomarkers might predict patient response to the Bria-IMT …
Basel Medical Group Ltd (Nasdaq: BMGL) has completed the acquisition of Bethesda Medical Pte. Ltd., a Singapore-based healthcare provider with three decades of experience in diagnostic imaging and outpatient medical services. The move strengthens Basel Medical’s footprint in Singapore and initiates its broader strategy …
The European Commission has approved the conversion of the conditional marketing approval (CMA) for FILSPARI into a standard marketing authorization (MA) for the treatment of primary IgA nephropathy (IgAN) in adults with a urine protein excretion of ≥1.0 g/day. This authorization applies across all …
Merck KGaA, Darmstadt, Germany (DAX:MRK), a leading science and technology company, has announced a definitive agreement to acquire SpringWorks Therapeutics, Inc. (Nasdaq:SWTX), a biopharmaceutical company focused on rare diseases and cancer. The deal, valued at approximately $3.9 billion, will see Merck KGaA purchase SpringWorks …
USANA Health Sciences, Inc. (NYSE:USNA) released stronger-than-expected quarterly earnings. The health and wellness company reported first-quarter earnings per share (EPS) of $0.73, surpassing analysts’ consensus forecast of $0.70. Revenue also outpaced expectations, coming in at $249.54 million against estimates of $243.08 million. However, year-over-year …
Intuitive Surgical, Inc. (Nasdaq:ISRG) has reported financial results for the first quarter ended March 31, 2025. the results are driven by the demand for robotic-assisted procedures and the adoption of its next-gen da Vinci 5 system powered growth across the board.
Walgreens (NASDAQ:WBA) Boots Alliance has agreed to pay up to $350 million to resolve allegations that it filled millions of unlawful prescriptions for opioids and other controlled substances over more than a decade, the U.S. Department of Justice (DOJ) announced on Friday.
Evotec SE (NASDAQ: EVO) has published its full-year 2024 financial results, along with its strategic roadmap through 2028. Following a comprehensive review process, the company announced a realignment to focus on core areas of scientific and technological expertise within drug discovery and biologics development.
Verve Therapeutics (NASDAQ:VERV) exploded higher Tuesday after releasing encouraging early-stage clinical data for its experimental gene-editing treatment VERVE-102, aimed at treating heterozygous familial hypercholesterolemia (HeFH) and premature coronary artery disease.
Please wait processing your request...